ArticleInvestigative ophthalmology & visual science2025
Glaucomatous, Glaucoma-Like, and Non-Glaucomatous Optic Neuropathy in High Myopia: The Two-Continent Study.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Binocular Non-Cycloplegic Ocular Parameters for Modeling Cycloplegic SER in Children.Translational vision science & technology · 2026Article
- Interaction of Myopic Optic Neuropathy (MON) and Glaucomatous Optic Neuropathy (GON): Pathophysiology and Clinical Implications.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to examine prevalences of glaucomatous (GON), glaucoma-like (GLON), and non-glaucomatous optic neuropathy (NGON) in highly myopic individuals. Methods: The population-based investigations of the Ural Eye and Medical Study (UEMS; n = 5899 participants; aged = 40+ years), Ural Very Old Study (UVOS; n = 684 participants; aged = 85+ years), Ural Children Eye Study (UCES; n = 4933 participants; aged = 11.8 ± 3.2 years), Central India Eye and Medical Study (CIEMS; n = 4711 participants, aged = 30+ years), and Beijing Eye Study (BES; n = 4439 participants, aged = 40+ years) were conducted in Bashkortostan/Russia, Nagpur/India, and Beijing/China, respectively. Results: Prevalences of NGON and GLON/GON in the UEMS (n = 116 highly myopic individuals), UVOS (n = 13), UCES (n = 101), CIEMS (n = 47), and BES (n = 149 eyes) were 34 of 116 (29.3%, 95% confidence interval [CI] = 21.0-38.0) and 10 of 116 (8.6%, 95% CI = 3.1-14.1), 4 of 13 (31%, 95% CI = 2-60), and 4 of 13 (31%, 95% CI = 2-60), 0 of 101 and 0 of 101, and 16 of 47 (34.0%, 95% CI = 20.0-48.1) and 14 of 47 (29.8%, 95% CI = 16-43), and 34 of 149 (22.8%, 95% CI = 16-30) and 20 of 149 (13.4%, 95% CI = 8-19), respectively. In all cohorts, higher NGON prevalence and degree were associated (most P < 0.01) with longer axial length and wider myopic parapapillary beta/gamma zone. Higher GLON/GON prevalence and degree were associated (most P < 0.01) with larger optic disc size and, less significantly, with longer axial length. The proportion of eyes with elevated IOP or anti-glaucomatous therapy was 3 of 10 (30%), 1 of 4 (25%), 0 of 14 (0%), and 1 of 20 (5%), respectively. Conclusions: Highly myopic eyes had considerable prevalences of NGON and GLON/GON, usually higher than 20% and 10%, respectively. The single IOP reading was ≤21 millimeters of mercury (mm Hg) in ≥70% of the eyes with GLON/GON. NGON (associated with large parapapillary myopic beta/gamma zone) and GLON/GON (associated with large optic disc size) differed in their relationships. Prevalences of both optic neuropathies increased in a nonlinear manner with longer axial length, reaching values of 50% to 100% in extreme high myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.